Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16832891 | 0.78 | EGLN2 (0.33) | EGLN2KCNK13 | |
| SCHEMBL3294798 | 0.78 | EGLN2 (0.41) | CYP2A6EGLN2NQO1PANK3 | |
| SCHEMBL45848 | 0.78 | TP53 (0.33) | — | |
| SCHEMBL30942641 | 0.75 | TKT (0.33) | EGLN2KCNK13 | |
| SCHEMBL24141637 | 0.74 | — | — | |
| SCHEMBL30942638 | 0.74 | EGLN2 (0.30) | EGLN2KCNK13 | |
| SCHEMBL9855728 | 0.70 | APP (0.46) | — | |
| SCHEMBL9855211 | 0.70 | ACACB (0.44) | NQO1 | |
| SCHEMBL3906820 | 0.70 | — | — | |
| SCHEMBL20122654 | 0.68 | AR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-06 | — | — | US | disclosed |
| EP-3402781-B1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2017044434-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-16 | — | — | WO | disclosed |
| EP-2686321-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | ICMT, INMT, BHMT | CYP2A6 1209/4885EGLN2 3934/4885KDM4E 2117/4885 |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | ICMT, INMT, BHMT | CYP2A6 1209/4885EGLN2 3934/4885KDM4E 2117/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | CYP2A6 1724/4885EGLN2 1712/4885KDM4E 1141/4885 |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | CYP2A6 3164/4885EGLN2 3260/4885KDM4E 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.